We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Clinical Digital PCR System for Oncology Testing Delivers Highly Accurate Diagnostic Results

By LabMedica International staff writers
Posted on 03 Oct 2024
Print article
Image: The QIAcuityDx digital PCR system has been launched for clinical testing in oncology (Photo courtesy of QIAGEN)
Image: The QIAcuityDx digital PCR system has been launched for clinical testing in oncology (Photo courtesy of QIAGEN)

QIAGEN N.V. (Venlo, the Netherlands) has launched the QIAcuityDx Digital PCR System, a key addition to its digital PCR portfolio now geared toward clinical diagnostics. QIAcuityDx simplifies clinical testing by delivering highly accurate, absolute quantification of target DNA and RNA, making it ideal for applications such as monitoring cancer progression and complementing routine cancer diagnostics, which are typically performed using Next Generation Sequencing (NGS).

The QIAcuityDx platform is an IVD medical device that integrates partitioning, thermocycling, and imaging into a seamless 5-plex workflow within a single instrument, eliminating the need for extra equipment. Capable of processing up to four nanoplates simultaneously, it reduces laboratory space requirements, servicing demands, and operator time. Labs already familiar with QIAcuity will find the same fast and simple nanoplate-based workflow, where samples are partitioned into thousands of tiny sections and reactions are read simultaneously to detect even faint DNA and RNA signals. The QIAcuityDx system offers higher throughput, enables partition imaging, enhances precision and sensitivity, cuts processing time to just two hours, and reduces the risk of cross-contamination—essential for oncology and infectious disease applications.

The QIAcuityDx software is tailored for diagnostic use, offering an intuitive interface and a comprehensive audit trail to meet modern laboratory standards. It features an IVD mode with validated assay plug-ins and automated analysis, alongside a utility mode that provides flexibility for laboratories developing their own tests (LDTs) and research applications. The system supports continuous sample loading and flexible scheduling, allowing for urgent testing without compromising patient results. To ensure diagnostic compliance, QIAcuityDx includes a bi-directional LIMS (Laboratory Information Management System) interface for seamless integration with electronic patient records. It also comes with QIAcuityDx-optimized universal master mix, nanoplates manufactured under strict regulatory standards, a validated installation process with audit-ready reports, and 5-channel calibration to improve image processing and reproducibility.

QIAGEN is rapidly expanding the QIAcuityDx System’s application menu, with a BCR::ABL assay for oncohematology set for FDA submission in 2025. The platform also provides access to QIAGEN’s full range of research-use products via its GeneGlobe platform. Additionally, QIAGEN has partnered with three pharmaceutical companies to develop companion diagnostics on the QIAcuityDx, advancing digital PCR’s role in precision medicine. Looking ahead, QIAGEN plans to collaborate with third parties to develop new assays for the platform. The QIAcuityDx instrument and its accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe.

“With the QIAcuityDx, we are bringing our precise and efficient digital PCR platform into the clinical space, reflecting our commitment to meeting the evolving needs of clinical labs in monitoring and minimal residual disease testing during patient treatment,” said Fernando Beils, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “By integrating all necessary functions into a single device, we are simplifying workflows and reducing operational costs for clinical labs, while instilling confidence in highly accurate and reliable diagnostic results.”

Related Links:
QIAGEN N.V.

Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Adenovirus Detection Kit
REALQUALITY RQ-ADENO
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Immunology

view channel
Image: An immune response is initiated when an antigen-presenting cell (pink) presents foreign material to a T-cell (blue) (Photo courtesy of JAX)

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

A growing tumor is influenced not only by the tumor cells themselves but also by the surrounding tissue, which alters its biology. Immune cells communicate by transferring vital signaling proteins to their... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: LMU’s Professor Frederick Klauschen developed the novel approach that can improve diagnostic accuracy (Photo courtesy of LMU Munich)

AI Tool Uses Imaging Data to Detect Less Frequent GI Diseases

Artificial intelligence (AI) is already being utilized in various medical fields, demonstrating significant potential in aiding doctors in diagnosing diseases through imaging data. However, training AI... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.